Stride crossed pandemic highs and sparked a breakout, underscoring its shift to a recurring revenue model. Read why I rate ...

Novo Nordisk A/S is a strong buy for 2024, with cutting-edge drug approvals, cost savings, and robust long-term growth potential. Click for my NVO stock update.